Peanut Allergy Treatment — Food Allergy Care Center

Understanding Peanut Allergies and Treatment Approaches

Peanut allergies are increasingly acknowledged as significant health concerns that typically persist into adulthood and can worsen over time without proper intervention. Unlike traditional allergy management that relied solely on strict avoidance and emergency preparedness with epinephrine auto-injectors, modern immunotherapy approaches now offer patients the opportunity to build tolerance and reduce their risk of severe reactions. Food Allergy Care Center's comprehensive food allergy treatment uses advanced testing, diagnosis, and oral immunotherapy programs to address gaps that traditional allergy care simply doesn't cover.

We use advanced testing and diagnosis to identify the specific peanut proteins triggering your reactions, then design personalized oral immunotherapy protocols around those findings. Our center offers FDA-approved Palforzia treatment alongside custom OIT protocols built to match individual patient needs. From initial evaluation through maintenance dosing, we incorporate emergency preparedness training at every stage of the process.

Real-world results speak louder than theory. A child who previously couldn't attend birthday parties without anxiety can eventually enjoy school events knowing they're protected. A teenager no longer needs to decline social invitations due to contamination fears. These shifts from constant vigilance to genuine peace of mind shape how we approach treatment.

Advanced Peanut Allergy Testing and Diagnosis

Getting an accurate diagnosis is crucial for effectively treating peanut allergies. We start with skin prick testing to identify immediate IgE-mediated reactions, then follow up with serum-specific IgE level measurements to quantify how severe the sensitization is.

Component testing represents a critical advancement in allergy diagnosis, allowing us to identify specific peanut proteins (Ara h 1, Ara h 2, Ara h 3, Ara h 6, and others) responsible for triggering reactions. Ara h 2 and Ara h 6 levels particularly predict severity and persistence, while Ara h 8 indicates cross-reactivity with birch pollen. This molecular-level analysis guides treatment decisions and helps predict therapeutic outcomes.

When clinically appropriate, oral food challenges establish precise baseline tolerance levels under controlled medical supervision. These challenges provide definitive confirmation of allergy status and determine the starting dose for oral immunotherapy protocols.

Testing results shape everything that comes next. Patients with high Ara h 2 levels and history of severe reactions receive modified protocols, while those with lower sensitization levels may qualify for accelerated desensitization programs. We accept major insurance providers including Aetna, UnitedHealthcare, and Blue Shield of California, ensuring accessibility for comprehensive evaluation.

Palforzia Treatment Protocol

The FDA approved Palforzia as the first oral immunotherapy specifically designed for peanut allergy management in patients aged 4-17 years. This standardized peanut allergen powder contains precisely measured amounts of peanut proteins, enabling controlled desensitization under medical supervision.

The treatment journey begins with an initial dose escalation that takes place in our clinic over several hours, followed by a gradual up-dosing process that spans 22 weeks with biweekly dose increases. Finally, maintenance therapy involves daily 300mg doses. We monitor closely for allergic reactions during each phase and adjust doses based on how individual patients respond.

Patient selection criteria include confirmed peanut allergy through testing, ability to follow protocol requirements, and absence of uncontrolled asthma or eosinophilic esophagitis. We exclude patients with severe cardiovascular disease or those unable to avoid alcohol, exercise, and illness during treatment periods.

Safety monitoring happens at every single visit. We check vital signs, evaluate for any symptoms, and make sure patients know exactly what to do if a reaction occurs. Patients receive comprehensive training on recognizing reactions, proper epinephrine administration, and when to seek emergency care. After 12-18 months of therapy, most patients show protection against accidental exposures of 300-600mg peanut protein.

Insurance coverage through Cigna, Medicare, and Tricare supports patient access to this evidence-based treatment approach.

Custom Oral Immunotherapy (OIT) Protocols

While Palforzia provides standardized treatment for pediatric patients, custom oral immunotherapy protocols address the unique needs of patients requiring personalized approaches. Our individualized dosing protocols accommodate patients with complex medical histories, multiple food allergies, or specific tolerance patterns that fall outside standardized treatment parameters.

Custom OIT flexibility allows for modified allergen preparations using whole peanut flour, roasted peanut powder, or specific protein fractions based on component testing results. Dosing schedules adapt to patient-specific factors including reaction history, concurrent medications, seasonal allergies, and lifestyle considerations. Our proprietary Rapid Desensitization Protocol reduces standard treatment timelines from 12 months to 8 months for qualified pediatric patients by utilizing micro-dose advancement techniques developed exclusively at our center. Some patients benefit from slower escalation phases, while others tolerate accelerated protocols under close medical supervision.

Multi-allergen OIT integration becomes particularly valuable for patients with tree nut, milk, or egg allergies alongside peanut sensitization. Sequential treatment approaches manage multiple allergens systematically, while simultaneous protocols may benefit carefully selected patients with appropriate risk profiles.

Pediatric and adult patients require different risk stratification approaches. Adult patients often present with more severe reactions and require modified starting doses, while pediatric protocols consider developmental factors and family compliance capabilities. Our treatment accepts coverage through Anthem Blue Cross, UnitedHealthcare, and Tricare, ensuring accessibility for customized care.

Emergency preparedness training accompanies all custom protocols, with personalized action plans reflecting individual patient risk factors and treatment goals.

Treatment Phases: From Initial Evaluation to Maintenance

Successful peanut allergy treatment requires systematic progression through distinct phases, each designed to build upon previous achievements while maintaining patient safety. Our comprehensive approach ensures optimal outcomes through careful monitoring and protocol adjustments.

Initial evaluation encompasses detailed medical history review, comprehensive allergy testing including component analysis, and baseline tolerance assessment. Treatment planning incorporates individual risk factors, concurrent medical conditions, and family preferences to establish personalized protocols. Emergency action plan development and epinephrine training occur during this foundational phase.

Dose escalation begins with carefully calculated starting doses based on testing results and proceeds through systematic increases under medical supervision. During this phase, we track symptoms closely, watch for vital sign changes, and assess how well each patient tolerates the advancing doses. Dose adjustments accommodate individual responses while maintaining safety parameters. This phase typically spans 4-6 months depending on protocol selection and patient tolerance.

Home dosing transition provides patients with comprehensive instructions for daily administration, reaction recognition, and emergency management. Detailed safety protocols include timing restrictions around exercise, illness, and alcohol consumption. Regular check-ins ensure protocol adherence and address emerging concerns.

Maintenance dosing strategies focus on sustaining protective tolerance through consistent daily doses while monitoring for breakthrough reactions. Long-term follow-up includes periodic testing to assess immunological changes and treatment effectiveness. Insurance coverage through Aetna, Cigna, and Medicare supports ongoing maintenance care requirements.

Safety Protocols and Emergency Preparedness

Comprehensive emergency preparedness training begins before treatment initiation and continues throughout every phase of oral immunotherapy. We ensure patients and families develop confidence in managing allergic reactions while maintaining treatment safety.

Emergency action planning incorporates individual risk factors, reaction patterns, and treatment phase considerations. Each patient receives personalized protocols detailing symptom recognition, medication timing, and emergency contact procedures. Action plans undergo regular updates as treatment progresses and tolerance develops.

Epinephrine training encompasses proper auto-injector technique, storage requirements, and expiration monitoring. Families practice injection procedures during clinic visits and receive detailed guidance on when epinephrine administration becomes necessary versus when antihistamines suffice for mild reactions.

Office-based emergency protocols during dose escalation visits include immediate access to emergency medications, cardiac monitoring capabilities, and established relationships with emergency services. Our medical team maintains advanced life support training and emergency equipment readily available throughout all treatment sessions.

Ongoing risk assessment evaluates patient tolerance, identifies concerning reaction patterns, and adjusts emergency protocols accordingly. Seasonal allergy flares, concurrent illnesses, and medication changes trigger emergency plan reviews to ensure continued safety. Insurance providers including UnitedHealthcare, Anthem Blue Cross, and Aetna support comprehensive emergency preparedness training as integral components of successful treatment outcomes.

Treatment Outcomes and Long-term Management

Clinical studies show that 67-80% of patients achieve protection against accidental exposures equivalent to 1-2 peanuts after completing our treatment protocols. Most patients develop tolerance to 300-1000mg of peanut protein, providing substantial protection against real-world contamination scenarios.

Long-term maintenance requires daily dosing commitment, typically continuing indefinitely to preserve protective tolerance. Patients must maintain consistent dosing schedules while avoiding exercise, alcohol, and illness-related interruptions that can trigger reactions. Lifestyle modifications become permanent components of successful treatment outcomes.

Sustained tolerance monitoring includes periodic food challenges to assess protection levels and immunological testing to track allergen-specific antibody changes. Some patients achieve sustained unresponsiveness, allowing treatment discontinuation, while others require ongoing maintenance dosing for continued protection.

Multi-allergen management integration becomes essential for patients with tree nut, milk, or egg allergies alongside peanut treatment. Sequential immunotherapy approaches address additional allergens systematically, while emergency preparedness protocols accommodate multiple food allergy risks. Our comprehensive management accepts coverage through Medicare, Tricare, and Blue Shield of California for ongoing care coordination.

Treatment modifications may include dose adjustments during illness, seasonal allergy flares, or breakthrough reactions, ensuring sustained protection while maintaining safety parameters throughout long-term management.

Comprehensive Services and Support

Our comprehensive care model extends beyond immunotherapy treatment through integrated support services designed to optimize patient outcomes throughout the entire journey. HIPAA-compliant telemedicine through Doxy.me enables convenient follow-up visits for patients requiring ongoing monitoring while reducing travel burdens, particularly valuable during maintenance phases or when addressing treatment concerns between scheduled appointments.

Coordinated allergy management addresses the reality that peanut allergy patients frequently present with concurrent asthma, seasonal allergies, and environmental sensitivities. Our integrated approach manages these overlapping conditions simultaneously, ensuring optimal treatment outcomes while preventing interference between different therapeutic protocols. This comprehensive strategy proves particularly beneficial for patients with multiple food allergies requiring sequential or combined immunotherapy approaches.

Educational resources empower families with detailed training materials, reaction logs, and emergency preparedness tools specifically tailored to oral immunotherapy requirements. Our support system includes regular family education sessions addressing treatment adherence, lifestyle modifications, and long-term management strategies that extend far beyond clinical visits.

Collaborative care coordination with primary care physicians, pediatricians, and other specialists ensures seamless treatment integration while maintaining comprehensive medical oversight. Insurance acceptance through Aetna, UnitedHealthcare, and Anthem Blue Cross facilitates coordinated care delivery across multiple providers, ensuring patients receive comprehensive allergy management without coverage gaps or administrative barriers that could compromise treatment continuity.

Insurance Coverage and Accessibility

Food Allergy Care Center accepts comprehensive insurance coverage to ensure peanut allergy treatment remains accessible for families across diverse financial backgrounds. We accept major insurance plans including Aetna, Anthem Blue Cross, Blue Shield of California, Cigna, UnitedHealthcare, Medicare, and Tricare, providing broad coverage options for both pediatric and adult patients requiring oral immunotherapy services.

Insurance coverage considerations for oral immunotherapy encompass initial evaluation visits, comprehensive allergy testing including component analysis, treatment phase monitoring appointments, and ongoing maintenance care. Most insurance providers recognize oral immunotherapy as medically necessary treatment for documented peanut allergies, though prior authorization may be required for Palforzia or custom OIT protocols.

Our convenient location at 16661 Ventura Blvd # 409, Suit 409, Encino, CA 91436 provides accessible care for patients throughout the greater Los Angeles area. We are open Monday through Friday, with hours beginning at 8:00 AM and closing at 12:00 PM on Friday. HIPAA-compliant telemedicine options through Doxy.me reduce travel requirements for maintenance phase monitoring and follow-up consultations, ensuring continuous care accessibility while minimizing schedule disruptions for busy families managing long-term treatment protocols.